Rani Therapeutics

Update in progress

RANI (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company developing oral delivery of biologics and drugs to replace injections. Its RaniPill capsule is a drug-agnostic oral platform for oligonucleotides, peptides, proteins, and antibodies. Pipeline includes RT‑105 (preclinical anti-TNF‑alpha for RA), RT‑116 (obesity), RT‑117 (rare diseases), RT‑111 (ustekinumab biosimilar). Collaborations: ProGen for RT‑114 obesity and Chugai for an oral hemophilia program. Founded 2012; based in San Jose, California.

Company score

Sentiment: 0.43; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.20; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.12; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.09; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.26; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive